Deal analysis part three – the undecided
Of the big oncology deals since 2016, there are still plenty that could go either way.
The new normal in US oncology approvals
Nearly two thirds of key oncology filings are expedited; and what about the ones that aren’t?
Deal analysis part two – the good
A look at big oncology deals since 2016 finds outright success stories hard to come by.
Deal analysis part one – the bad
A look at big oncology deals since 2016 suggests that there have been more duds than successes.
Make or break time for Iovance
Lifileucel heads up the list of upcoming US FDA catalysts.
Regeneron works to secure fianlimab
A just revealed phase 3 trial will apparently pit a fixed-dose combo head to head against Opdualag.
Caribou aims to set itself apart from the allogeneic Car-T herd
For now, the group is sticking with what it knows ahead of a big year in lymphoma.
